ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension
Authors:
- Grant R. BudasGBGrant R. Budas
- Mario BoehmMBMario Boehm
- Baktybek KojonazarovBKBaktybek Kojonazarov
- Gayathri ViswanathanGVGayathri Viswanathan
- Xia TianXTXia Tian
- Swathi VeerojuSVSwathi Veeroju
- Tatyana NovoyatlevaTatyana Novoyatleva
- Friedrich GrimmingerFGFriedrich Grimminger
- Ford Hinojosa-KirschenbaumFHFord Hinojosa-Kirschenbaum
- Hossein A. GhofraniHGHossein A. Ghofrani
- Norbert WeissmannNWNorbert Weissmann
- Werner SeegerWSWerner Seeger
- 1 February 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 197 (3) , 373-385
Abstract
Rationale: Progression of pulmonary arterial hypertension (PAH) is associated with pathological remodeling of the pulmonary vasculature and the right ventricle (RV). Oxidative stress drives the remodeling process through activation of MAPKs (mitogen-activated protein kinases), which stimulate apoptosis, inflammation, and fibrosis. Objectives: We investigated whether pharmacological inhibition of the redox-sensitive apical MAPK, ASK1 (apoptosis signal-regulating kinase 1), can halt the progression of pulmonary vascular and RV remodeling. Methods: A selective, orally available ASK1 inhibitor, GS-444217, was administered to two preclinical rat models of PAH (monocrotaline and Sugen/hypoxia), a murine model of RV pressure overload induced by pulmonary artery banding, and cellular models. Measurements and Main Results: Oral administration of GS-444217 dose dependently reduced pulmonary arterial pressure and reduced RV hypertrophy in PAH models. The therapeutic efficacy of GS-444217 was associated with reduced ASK1 phosphorylation, reduced muscularization of the pulmonary arteries, and reduced fibrotic gene expression in the RV. Importantly, efficacy was observed when GS-444217 was administered to animals with established disease and also directly reduced cardiac fibrosis and improved cardiac function in a model of isolated RV pressure overload. In cellular models, GS-444217 reduced phosphorylation of p38 and JNK (c-Jun N-terminal kinase) induced by adenoviral overexpression of ASK1 in rat cardiomyocytes and reduced activation/migration of primary mouse cardiac fibroblasts and human pulmonary adventitial fibroblasts derived from patients with PAH. Conclusions: ASK1 inhibition reduced pathological remodeling of the pulmonary vasculature and the right ventricle and halted progression of pulmonary hypertension in rodent models. These preclinical data inform the first description of a causal role of ASK1 in PAH disease pathogenesis.Keywords
This publication has 51 references indexed in Scilit:
- Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?Current Hypertension Reports, 2016
- Right Heart Adaptation to Pulmonary Arterial HypertensionJACC, 2013
- Relevant Issues in the Pathology and Pathobiology of Pulmonary HypertensionJACC, 2013
- Molecular pathogenesis of pulmonary arterial hypertensionJournal of Clinical Investigation, 2012
- Mechanisms of disease: pulmonary arterial hypertensionNature Reviews Cardiology, 2011
- Contribution of oxidative stress to pulmonary arterial hypertensionWorld Journal of Cardiology, 2010
- Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertensionEuropean Respiratory Journal, 2009
- The Right Ventricle Under PressureChest, 2009
- Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary VasculatureCirculation Research, 2007
- Oxidative Stress in Severe Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2004